Terms: = Pancreatic cancer AND SF3B1, ENSG00000115524, 23451, O75533, SF3b155, SAP155, PRPF10, PRP10 AND Treatment
3 results:
1. Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells.
North K; Benbarche S; Liu B; Pangallo J; Chen S; Stahl M; Bewersdorf JP; Stanley RF; Erickson C; Cho H; Pineda JMB; Thomas JD; Polaski JT; Belleville AE; Gabel AM; Udy DB; Humbert O; Kiem HP; Abdel-Wahab O; Bradley RK
Nat Biotechnol; 2022 Jul; 40(7):1103-1113. PubMed ID: 35241838
[TBL] [Abstract] [Full Text] [Related]
2. Dysregulated splicing factor sf3b1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
Alors-Perez E; Blázquez-Encinas R; Alcalá S; Viyuela-García C; Pedraza-Arevalo S; Herrero-Aguayo V; Jiménez-Vacas JM; Mafficini A; Sánchez-Frías ME; Cano MT; Abollo-Jiménez F; Marín-Sanz JA; Cabezas-Sainz P; Lawlor RT; Luchini C; Sánchez L; Sánchez-Hidalgo JM; Ventura S; Martin-Hijano L; Gahete MD; Scarpa A; Arjona-Sánchez Á; Ibáñez-Costa A; Sainz B; Luque RM; Castaño JP
J Exp Clin Cancer Res; 2021 Dec; 40(1):382. PubMed ID: 34857016
[TBL] [Abstract] [Full Text] [Related]
3. sf3b1 mutations constitute a novel therapeutic target in breast cancer.
Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
[TBL] [Abstract] [Full Text] [Related]
